These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35090807)

  • 1. Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial.
    Weatherald J; Thakrar MV; Varughese RA; Kularatne M; Liu J; Harper L; Kiamanesh O; Fine N; Orlikow E; Nwaroh C; Thornton C; Swiston J; Kolkman L; Brunner NW; Helmersen D; Hirani N
    J Heart Lung Transplant; 2022 May; 41(5):563-567. PubMed ID: 35090807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
    J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
    Issapour A; Frank B; Crook S; Hite MD; Dorn ML; Rosenzweig EB; Ivy DD; Krishnan US
    Pediatr Pulmonol; 2022 Mar; 57(3):724-733. PubMed ID: 34921523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
    Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of riociguat in combination therapies for pulmonary arterial hypertension.
    Rahaghi FF; Trivieri MG; Sahay S
    Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
    Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
    D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
    J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
    Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
    Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
    Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
    Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
    Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
    Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
    Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
    Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.